Adjuvant Therapies for Patients With HCC and MVI

NCT02436902 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

240

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

PROCEDURE: TACE
DRUG: Sorafenib
DRUG: TACE plus sorafenib
OTHER: empty control

Sponsor

Guangxi Medical University